Tarsus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TARS Tarsus Pharmaceuticals Inc
TKPHF Takeda Pharmaceutical Co Ltd
O Realty Income Corp
HSTA Hestia Insight Inc
NRG NRG Energy Inc
MACK Merrimack Pharmaceuticals Inc
BMY Bristol-Myers Squibb Co
NDAQ Nasdaq Inc
UL Unilever PLC
SF Stifel Financial Corp
Go

Health Care : Pharmaceuticals |
Company profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Closing Price
$19.83
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
17,271
0

Company Profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
7.57x
Price/Book (MRQ)
2.40x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

December 2021
Current Month
325.2K
Previous Month
325.3K
Percent of Float
2.41%
Days to Cover
14.9970 Days

Share Information

TARS is in a share class of common stock
Float
14.8M
Shares Outstanding
20.7M
Institutions Holding Shares
70
61.60%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Michael Ackermann
  • Bobak AzamianPres.
  • Leo M. GreensteinCFO
  • Seshadri NeervannanCOO
  • Dianne C. Whitfield

Address

Insider Trading

During the most recent quarter, 69K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.